Welcome to our dedicated page for AKTIS ONCOLOGY news (Ticker: AKTS), a resource for investors and traders seeking the latest updates and insights on AKTIS ONCOLOGY stock.
Aktis Oncology, Inc. (Nasdaq: AKTS) is a clinical-stage oncology company focused on targeted radiopharmaceuticals for solid tumors, and its news flow reflects this specialization. Company announcements emphasize progress in its miniprotein radioconjugate platform, which is designed to deliver radioisotopes selectively to tumors while limiting exposure to normal tissues.
News related to Aktis Oncology includes capital markets milestones, such as the closing of its upsized initial public offering and the start of trading on the Nasdaq Global Select Market under the AKTS ticker. These updates provide context on how the company is financing its research and development activities in targeted alpha radiopharmaceuticals.
Investors and observers can also expect coverage of pipeline developments. Aktis Oncology has highlighted programs such as AKY-1189 and AKY-2519, as well as its most advanced program targeting Nectin-4 with a miniprotein radioconjugate that it describes as having multi-indication potential across multiple tumor types. News may discuss clinical progress, platform refinements, and efforts to expand the reach of its radiopharmaceutical candidates to larger patient populations.
Another recurring theme in Aktis Oncology news is its strategic collaboration with Eli Lilly and Company, which is intended to apply the company’s miniprotein platform to novel radioconjugates outside its proprietary pipeline. Updates may reference how this collaboration fits into the company’s broader strategy.
For readers following AKTS, the news page offers a way to track developments in its clinical programs, financing events, and partnership activities over time. Regularly reviewing this coverage can help provide a clearer picture of how the company’s radiopharmaceutical platform and solid tumor pipeline are evolving.
Akoustis Technologies, Inc. (NASDAQ: AKTS) will webcast its Q2 FY23 results on February 7, 2023, at 8:00 AM ET, followed by a Q&A session. The company continues to see strong demand for its Wi-Fi, 5G mobile, and infrastructure products, including its patented XBAW® filters. In Q2, they shipped 5G XBAW® wafers featuring advanced wafer-level packaging technology. Akoustis is ramping up production capacity at its New York facility to reach approximately 0.5 billion filters annually. With over 20 customer design wins, the firm is well-positioned for growth in the expanding RF filter market.
Akoustis Technologies has successfully closed an oversubscribed public offering, raising approximately $32 million by offering 12,545,454 shares at $2.75 each. The offering included a participation of over $1 million from management, notably a $900K investment from founder and CEO Jeff Shealy. The funds are designated for operations, business growth, capital expenditures, and R&D, alongside servicing outstanding debt. The offering was managed by B. Riley Securities, with additional management from Craig-Hallum Capital Group and Roth Capital Partners.
Akoustis aims to leverage these funds to enhance its manufacturing capabilities and capitalize on growth opportunities in the RF filter market.
Akoustis Technologies, Inc. (Nasdaq: AKTS) has announced the pricing of its underwritten public offering of 10,909,091 shares of common stock at $2.75 per share, aiming for gross proceeds of approximately $30 million. After underwriting discounts, net proceeds are expected to be around $28.2 million. Funds will support operations, capital expenditures, R&D, and potential strategic transactions. The offering's expected closing date is January 24, 2023, with a 30-day option for underwriters to purchase an additional 1,636,363 shares. B. Riley Securities is the book-running manager for this offering.
Akoustis Technologies, Inc. (NASDAQ: AKTS) has announced its first high-volume purchase order for a 5G mobile filter from a major Tier-1 RF component customer. This filter, manufactured using the XBAW® process, will be integrated into a multiplexer designed for 5G mobile devices, expected to ship in the first half of 2023. Akoustis's new wafer-level-package (WLP), developed in New York, addresses challenges in 5G and Wi-Fi coexistence. The company anticipates increased production capacity, aiming for approximately 0.5 billion filters annually. This order signifies strong demand and a robust sales funnel for Akoustis's RF filter solutions.
Akoustis Technologies (Nasdaq: AKTS) announced its intention to conduct an underwritten public offering of common stock, with plans to grant underwriters a 30-day option for additional shares. The offering's details, including size and terms, remain subject to market conditions. Proceeds from the offering will fund operations, including capital expenditures, research, debt servicing, and general corporate purposes. B. Riley Securities, Inc. acts as the sole book-running manager, with additional co-managers involved. A shelf registration statement for the offering is effective, with further details available in a forthcoming prospectus.
Akoustis Technologies has announced the acquisition of Grinding and Dicing Services (GDSI) for $20 million, comprising $14 million in cash, $2 million in stock, and a $4 million promissory note. This acquisition is immediately accretive, adding a high-margin premium services business that supports over 250 customers. The move aligns with Akoustis' strategy to reshore its semiconductor packaging capabilities under the CHIPS Act. GDSI will enhance rapid prototyping for Akoustis' XBAW filters and integrates the supply chain for national security applications.
Akoustis Technologies, Inc. (NASDAQ: AKTS) has achieved a milestone by securing its first design win in the 5G mobile sector from a leading Tier-1 RF component customer. The newly designed XBAW® RF filter will be integrated into a multiplexer for 5G mobile handsets, expected to ship in the first half of 2023. This filter utilizes a proprietary wafer-level package developed in Akoustis' New York facility, enhancing manufacturing efficiency. The company anticipates further applications for its XBAW® technology across various mobile devices and is ramping up production capacity to meet strong demand.
Akoustis Technologies (NASDAQ: AKTS) has successfully qualified its proprietary wafer-level-packaging (WLP) technology for 5G mobile and timing control markets. This technology aims to address supply chain challenges and enhance production capabilities at their New York facility. The first WLP packages are set to enter production early in 2023. Akoustis continues to see strong demand for its XBAW® filter products, anticipating significant revenue opportunities in 5G smartphones, tablets, and infrastructure. The company aims to reach a production capacity of approximately 0.5 billion filters per year.
Akoustis Technologies (NASDAQ: AKTS) reported a 195% year-over-year revenue increase, reaching $5.6 million for Q1 FY23. The company anticipates another record quarter in Q2 FY23 with revenue expected to rise 55%-70%. Despite supply chain challenges, demand for XBAW filters is robust across diverse markets. Akoustis plans to expand manufacturing in New York, capitalizing on the CHIPS Act. Their patent portfolio grew to 73 issued patents and 123 pending. Significant design wins were achieved in Wi-Fi and 5G sectors.
Akoustis Technologies, Inc. (NASDAQ: AKTS) announced its participation in several upcoming conferences during the December 2022 quarter. Key events include the 11th Annual Roth Technology Event on November 16, 2022, and the 13th Annual Craig-Hallum Alpha Select Conference on November 17, 2022. Management will host one-on-one meetings at these events. Akoustis is focused on expanding its production capabilities, aiming for an annual capacity of approximately 0.5 billion filters, while actively engaging in 5G and Wi-Fi 6 technology solutions.